Greenwich LifeSciences (GLSI) Q4 2025 earnings summary

Executive summary

• Focused on Phase III clinical trial Flamingo-01 for GLSI-100, an immunotherapy targeting HER2/neu-positive breast cancer to prevent recurrence; expansion into Europe with up to 150 sites planned.

• No revenue generated to date; net losses of $19.4M in 2025 and $17.4M in 2024, driven by R&D and clinical trial costs.

• Company remains a clinical-stage biopharma with ongoing need for additional capital to fund operations and clinical development.

Financial highlights

• Research and development expenses rose 11% to $17.2M in 2025, mainly due to increased Phase III trial costs.

• General and administrative expenses increased 3% to $2.2M in 2025.

• Net loss for 2025 was $19.4M, up from $17.4M in 2024.

• Cash balance at year-end 2025 was $6.2M, up from $4.1M at end of 2024, due to equity financing.

• No revenue recognized; accumulated deficit reached $87.1M as of December 31, 2025.

Outlook and guidance

• Company expects continued operating losses and significant expenses as clinical trials progress and commercialization preparations begin.

• Additional capital will be required to complete development and regulatory approval of GLSI-100.

• Strategic alternatives, including financings, alliances, or sale, are being considered to maximize shareholder value.